The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•4 May 2026•

1 min read

NanoViricides' NV-387 Receives FDA Orphan Drug Designation for Measles

Key Facts

1The US FDA granted Orphan Drug Designation to NanoViricides' NV-387 for the treatment of measles.

2The designation provides the company with tax credits and seven years of market exclusivity following approval.

NanoViricides has announced that its antiviral drug candidate, NV-387, has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of measles. This regulatory milestone is designed to accelerate the development and approval process for the drug in addressing the viral infection. Under this designation, the company becomes eligible for various financial incentives, including tax credits for qualified clinical trials. Most significantly, the status provides NanoViricides with seven years of market exclusivity upon potential final regulatory approval. This development is viewed as a positive step for the micro-cap biotech firm as it advances its clinical pipeline. Investors are now looking toward upcoming clinical milestones to gauge the long-term commercial potential of the treatment.